Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lysophospholipids | 40 | 2020 | 75 | 10.840 |
Why?
|
Blood Platelets | 49 | 2020 | 306 | 8.430 |
Why?
|
Phosphatidate Phosphatase | 14 | 2022 | 26 | 6.170 |
Why?
|
Thrombosis | 24 | 2022 | 263 | 5.690 |
Why?
|
Phosphoric Diester Hydrolases | 21 | 2020 | 49 | 4.920 |
Why?
|
Inflammation | 20 | 2020 | 671 | 4.070 |
Why?
|
Pulmonary Embolism | 7 | 2021 | 107 | 3.950 |
Why?
|
Platelet Aggregation Inhibitors | 25 | 2020 | 209 | 3.570 |
Why?
|
Thrombolytic Therapy | 8 | 2020 | 135 | 3.330 |
Why?
|
Platelet Activation | 18 | 2020 | 67 | 3.200 |
Why?
|
Signal Transduction | 32 | 2020 | 1846 | 2.710 |
Why?
|
Myocardial Infarction | 14 | 2021 | 464 | 2.340 |
Why?
|
Myocytes, Smooth Muscle | 8 | 2022 | 111 | 2.260 |
Why?
|
Animals | 100 | 2022 | 14801 | 2.240 |
Why?
|
Cardiovascular Diseases | 14 | 2020 | 484 | 2.160 |
Why?
|
Sphingosine | 9 | 2019 | 36 | 2.070 |
Why?
|
Fibrinolytic Agents | 8 | 2020 | 149 | 2.030 |
Why?
|
Atherosclerosis | 6 | 2019 | 273 | 1.960 |
Why?
|
Humans | 153 | 2022 | 52865 | 1.940 |
Why?
|
Venous Thromboembolism | 5 | 2020 | 68 | 1.940 |
Why?
|
Mice | 63 | 2022 | 6389 | 1.860 |
Why?
|
Coronary Artery Disease | 8 | 2019 | 328 | 1.850 |
Why?
|
Acute Coronary Syndrome | 6 | 2016 | 92 | 1.820 |
Why?
|
Muscle, Smooth, Vascular | 6 | 2020 | 167 | 1.750 |
Why?
|
Mice, Knockout | 27 | 2022 | 1001 | 1.600 |
Why?
|
Hemostasis | 8 | 2018 | 66 | 1.450 |
Why?
|
Cardiology | 2 | 2020 | 100 | 1.430 |
Why?
|
Aged | 41 | 2021 | 10428 | 1.380 |
Why?
|
Hemorrhage | 7 | 2019 | 197 | 1.330 |
Why?
|
Blood Vessels | 3 | 2015 | 84 | 1.320 |
Why?
|
Anticoagulants | 4 | 2020 | 273 | 1.310 |
Why?
|
Platelet Membrane Glycoproteins | 11 | 2018 | 35 | 1.300 |
Why?
|
Adipocytes | 2 | 2019 | 147 | 1.290 |
Why?
|
Male | 67 | 2021 | 28240 | 1.280 |
Why?
|
Risk Assessment | 7 | 2021 | 1415 | 1.260 |
Why?
|
Thrombin | 9 | 2017 | 55 | 1.240 |
Why?
|
Adipogenesis | 3 | 2018 | 56 | 1.220 |
Why?
|
Middle Aged | 39 | 2021 | 13614 | 1.170 |
Why?
|
Registries | 2 | 2020 | 551 | 1.170 |
Why?
|
Mice, Inbred C57BL | 26 | 2021 | 2060 | 1.170 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2014 | 45 | 1.150 |
Why?
|
Leukocytes | 7 | 2019 | 95 | 1.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 156 | 1.120 |
Why?
|
Obesity | 5 | 2019 | 1178 | 1.120 |
Why?
|
Myocardium | 4 | 2020 | 467 | 1.120 |
Why?
|
Integrins | 7 | 2020 | 39 | 1.100 |
Why?
|
Ticlopidine | 6 | 2015 | 59 | 1.100 |
Why?
|
Syncope | 4 | 2021 | 35 | 1.070 |
Why?
|
Female | 56 | 2021 | 28888 | 1.060 |
Why?
|
Neutrophils | 9 | 2020 | 162 | 1.050 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2018 | 308 | 1.040 |
Why?
|
Receptors, Lysophosphatidic Acid | 8 | 2016 | 13 | 1.030 |
Why?
|
Diet, High-Fat | 2 | 2019 | 215 | 1.010 |
Why?
|
Myocardial Ischemia | 3 | 2015 | 150 | 1.000 |
Why?
|
Pyrophosphatases | 6 | 2011 | 19 | 1.000 |
Why?
|
Stroke | 5 | 2019 | 529 | 0.990 |
Why?
|
Sepsis | 2 | 2020 | 239 | 0.980 |
Why?
|
Length of Stay | 4 | 2020 | 706 | 0.980 |
Why?
|
Heart Ventricles | 2 | 2017 | 270 | 0.950 |
Why?
|
Inflammation Mediators | 5 | 2019 | 147 | 0.940 |
Why?
|
Cell Movement | 11 | 2020 | 301 | 0.940 |
Why?
|
P-Selectin | 8 | 2015 | 43 | 0.920 |
Why?
|
Blood Coagulation | 7 | 2019 | 79 | 0.920 |
Why?
|
Intracranial Hemorrhages | 3 | 2019 | 42 | 0.910 |
Why?
|
Guideline Adherence | 3 | 2020 | 157 | 0.910 |
Why?
|
Time Factors | 19 | 2020 | 3434 | 0.900 |
Why?
|
Phosphodiesterase I | 5 | 2010 | 6 | 0.900 |
Why?
|
Cell Communication | 4 | 2016 | 73 | 0.890 |
Why?
|
Coronary Thrombosis | 3 | 2012 | 29 | 0.890 |
Why?
|
Multienzyme Complexes | 5 | 2010 | 47 | 0.880 |
Why?
|
Peroxidase | 2 | 2015 | 22 | 0.880 |
Why?
|
Adult | 25 | 2021 | 14316 | 0.880 |
Why?
|
Disease Models, Animal | 18 | 2020 | 1693 | 0.870 |
Why?
|
Hospitalization | 5 | 2019 | 670 | 0.860 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2022 | 56 | 0.860 |
Why?
|
Diet | 4 | 2019 | 612 | 0.860 |
Why?
|
Myocardial Revascularization | 2 | 2019 | 23 | 0.850 |
Why?
|
Platelet Aggregation | 14 | 2014 | 93 | 0.830 |
Why?
|
Cardiovascular System | 2 | 2013 | 54 | 0.830 |
Why?
|
Angiotensin II | 1 | 2022 | 177 | 0.810 |
Why?
|
Platelet Adhesiveness | 6 | 2014 | 21 | 0.800 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 26 | 0.800 |
Why?
|
Receptors, Lysophospholipid | 1 | 2020 | 1 | 0.800 |
Why?
|
Thrombocytopenia | 2 | 2019 | 94 | 0.790 |
Why?
|
Percutaneous Coronary Intervention | 7 | 2020 | 322 | 0.790 |
Why?
|
Coronary Vessels | 2 | 2012 | 202 | 0.780 |
Why?
|
Fibrinogen | 10 | 2011 | 47 | 0.770 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 81 | 0.770 |
Why?
|
Risk Factors | 16 | 2021 | 3984 | 0.760 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2019 | 103 | 0.760 |
Why?
|
Endothelial Cells | 4 | 2014 | 289 | 0.740 |
Why?
|
Sphingolipids | 2 | 2019 | 17 | 0.740 |
Why?
|
Aortic Valve Stenosis | 2 | 2019 | 79 | 0.740 |
Why?
|
Receptors, Purinergic | 1 | 2019 | 7 | 0.740 |
Why?
|
Tissue Plasminogen Activator | 2 | 2020 | 128 | 0.730 |
Why?
|
Plaque, Atherosclerotic | 3 | 2015 | 54 | 0.720 |
Why?
|
Research | 1 | 2019 | 116 | 0.720 |
Why?
|
Depression | 3 | 2021 | 596 | 0.720 |
Why?
|
Critical Pathways | 1 | 2019 | 39 | 0.720 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 8 | 2013 | 43 | 0.710 |
Why?
|
Anxiety | 1 | 2020 | 268 | 0.710 |
Why?
|
Fibrosis | 2 | 2017 | 216 | 0.710 |
Why?
|
Troponin I | 2 | 2017 | 23 | 0.700 |
Why?
|
Macrophages | 5 | 2020 | 413 | 0.690 |
Why?
|
Enoxaparin | 1 | 2018 | 26 | 0.690 |
Why?
|
Treatment Outcome | 20 | 2020 | 5631 | 0.690 |
Why?
|
Severity of Illness Index | 4 | 2019 | 1113 | 0.690 |
Why?
|
Sex Factors | 8 | 2021 | 813 | 0.690 |
Why?
|
Cell Proliferation | 4 | 2014 | 1124 | 0.680 |
Why?
|
Women's Health | 2 | 2009 | 117 | 0.680 |
Why?
|
Referral and Consultation | 1 | 2020 | 300 | 0.670 |
Why?
|
Diabetic Angiopathies | 2 | 2010 | 23 | 0.670 |
Why?
|
Heart Diseases | 1 | 2020 | 231 | 0.670 |
Why?
|
Patient Care Team | 2 | 2021 | 292 | 0.660 |
Why?
|
Aortic Valve | 1 | 2019 | 114 | 0.660 |
Why?
|
Bone Marrow Cells | 3 | 2015 | 245 | 0.650 |
Why?
|
Heart Valve Prosthesis | 1 | 2019 | 95 | 0.640 |
Why?
|
src-Family Kinases | 4 | 2014 | 60 | 0.640 |
Why?
|
Heart-Assist Devices | 1 | 2019 | 167 | 0.640 |
Why?
|
Aged, 80 and over | 12 | 2021 | 3624 | 0.630 |
Why?
|
Databases, Factual | 7 | 2019 | 698 | 0.630 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 316 | 0.630 |
Why?
|
Drug Design | 4 | 2012 | 148 | 0.620 |
Why?
|
PPAR gamma | 2 | 2009 | 78 | 0.620 |
Why?
|
Vasoconstrictor Agents | 1 | 2017 | 90 | 0.610 |
Why?
|
Inpatients | 2 | 2018 | 202 | 0.610 |
Why?
|
Carotid Artery Injuries | 3 | 2012 | 17 | 0.590 |
Why?
|
Anemia, Sickle Cell | 1 | 2017 | 99 | 0.590 |
Why?
|
Retrospective Studies | 14 | 2021 | 6065 | 0.590 |
Why?
|
Receptor, PAR-1 | 3 | 2014 | 11 | 0.590 |
Why?
|
Cells, Cultured | 12 | 2019 | 1842 | 0.580 |
Why?
|
Membrane Proteins | 3 | 2015 | 395 | 0.570 |
Why?
|
Platelet Function Tests | 7 | 2016 | 26 | 0.560 |
Why?
|
Aspirin | 5 | 2014 | 133 | 0.560 |
Why?
|
Creatine Kinase, MB Form | 1 | 2015 | 6 | 0.560 |
Why?
|
Megakaryocytes | 3 | 2011 | 26 | 0.550 |
Why?
|
Integrin alphaVbeta3 | 3 | 2010 | 8 | 0.550 |
Why?
|
Fluorobenzenes | 1 | 2015 | 23 | 0.550 |
Why?
|
Microcirculation | 3 | 2012 | 94 | 0.550 |
Why?
|
Drug Resistance | 5 | 2010 | 80 | 0.540 |
Why?
|
Secretory Vesicles | 1 | 2014 | 14 | 0.540 |
Why?
|
Models, Biological | 6 | 2012 | 872 | 0.530 |
Why?
|
Blood Pressure | 5 | 2011 | 598 | 0.530 |
Why?
|
Pyrimidines | 3 | 2015 | 198 | 0.530 |
Why?
|
Molecular Targeted Therapy | 2 | 2013 | 134 | 0.510 |
Why?
|
Capillary Permeability | 1 | 2014 | 42 | 0.510 |
Why?
|
Atrial Fibrillation | 5 | 2018 | 219 | 0.510 |
Why?
|
Heart Failure | 6 | 2019 | 548 | 0.510 |
Why?
|
Postoperative Complications | 2 | 2020 | 1083 | 0.500 |
Why?
|
Mice, Transgenic | 8 | 2018 | 725 | 0.500 |
Why?
|
Sulfonamides | 1 | 2015 | 153 | 0.490 |
Why?
|
Stents | 4 | 2009 | 386 | 0.480 |
Why?
|
Laser-Doppler Flowmetry | 2 | 2012 | 22 | 0.480 |
Why?
|
Age Factors | 8 | 2021 | 1262 | 0.480 |
Why?
|
Neovascularization, Physiologic | 3 | 2018 | 79 | 0.480 |
Why?
|
Hospital Mortality | 6 | 2021 | 471 | 0.470 |
Why?
|
Platelet Count | 3 | 2020 | 66 | 0.470 |
Why?
|
Mast Cells | 1 | 2013 | 71 | 0.460 |
Why?
|
Antigens, CD | 5 | 2013 | 263 | 0.460 |
Why?
|
Hematopoietic Stem Cells | 2 | 2014 | 231 | 0.460 |
Why?
|
Coronary Angiography | 3 | 2019 | 403 | 0.460 |
Why?
|
Venous Thrombosis | 3 | 2021 | 111 | 0.450 |
Why?
|
von Willebrand Factor | 2 | 2021 | 55 | 0.450 |
Why?
|
Coronary Circulation | 1 | 2012 | 65 | 0.450 |
Why?
|
Peptide Fragments | 3 | 2017 | 266 | 0.450 |
Why?
|
Hematocrit | 1 | 2011 | 53 | 0.440 |
Why?
|
Neoplasms | 2 | 2019 | 1258 | 0.440 |
Why?
|
Adipose Tissue, Brown | 1 | 2012 | 43 | 0.440 |
Why?
|
Pneumonia | 1 | 2013 | 127 | 0.440 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 445 | 0.440 |
Why?
|
Acute Disease | 4 | 2019 | 417 | 0.440 |
Why?
|
Defibrillators, Implantable | 3 | 2017 | 80 | 0.430 |
Why?
|
Connexins | 1 | 2011 | 31 | 0.430 |
Why?
|
Vasodilator Agents | 1 | 2012 | 111 | 0.430 |
Why?
|
Integrin beta3 | 5 | 2003 | 11 | 0.430 |
Why?
|
Adipose Tissue | 4 | 2019 | 245 | 0.420 |
Why?
|
Anemia | 1 | 2011 | 94 | 0.420 |
Why?
|
United States | 11 | 2019 | 5032 | 0.420 |
Why?
|
Erythrocyte Transfusion | 1 | 2011 | 88 | 0.410 |
Why?
|
Survival Rate | 6 | 2020 | 1012 | 0.410 |
Why?
|
Femoral Artery | 4 | 2014 | 131 | 0.400 |
Why?
|
Pulmonary Artery | 1 | 2011 | 151 | 0.390 |
Why?
|
Incidence | 7 | 2019 | 1088 | 0.390 |
Why?
|
T-Lymphocytes | 1 | 2012 | 340 | 0.380 |
Why?
|
Coronary Artery Bypass | 3 | 2020 | 139 | 0.380 |
Why?
|
Critical Illness | 1 | 2013 | 327 | 0.380 |
Why?
|
Prospective Studies | 4 | 2020 | 2453 | 0.370 |
Why?
|
Phosphorylation | 12 | 2014 | 644 | 0.370 |
Why?
|
Coronary Stenosis | 2 | 2007 | 110 | 0.360 |
Why?
|
Aortic Diseases | 1 | 2009 | 57 | 0.360 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2010 | 137 | 0.350 |
Why?
|
Phosphoric Monoester Hydrolases | 3 | 2015 | 30 | 0.350 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2008 | 15 | 0.350 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2008 | 48 | 0.350 |
Why?
|
Calgranulin A | 2 | 2020 | 9 | 0.350 |
Why?
|
Intensive Care Units | 2 | 2020 | 219 | 0.340 |
Why?
|
Interleukin-6 | 4 | 2019 | 318 | 0.340 |
Why?
|
Pyrazoles | 3 | 2018 | 118 | 0.330 |
Why?
|
Peptides | 3 | 2013 | 283 | 0.330 |
Why?
|
Pyridones | 2 | 2018 | 43 | 0.330 |
Why?
|
Administration, Oral | 2 | 2020 | 481 | 0.330 |
Why?
|
Vascular Diseases | 1 | 2008 | 77 | 0.330 |
Why?
|
Flow Cytometry | 7 | 2015 | 582 | 0.330 |
Why?
|
Hirudins | 1 | 2007 | 21 | 0.330 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2007 | 23 | 0.330 |
Why?
|
Plasminogen | 1 | 2007 | 3 | 0.330 |
Why?
|
Plasminogen Activators | 1 | 2007 | 5 | 0.320 |
Why?
|
Arteries | 3 | 2018 | 111 | 0.320 |
Why?
|
Blood Preservation | 2 | 2020 | 31 | 0.320 |
Why?
|
Gene Expression Regulation | 7 | 2019 | 1147 | 0.310 |
Why?
|
Pneumothorax | 2 | 2017 | 21 | 0.310 |
Why?
|
Monocytes | 4 | 2019 | 158 | 0.310 |
Why?
|
Inflammasomes | 4 | 2022 | 67 | 0.310 |
Why?
|
Lipid Metabolism | 4 | 2022 | 210 | 0.310 |
Why?
|
Platelet Transfusion | 3 | 2020 | 34 | 0.300 |
Why?
|
Endothelium, Vascular | 4 | 2018 | 298 | 0.300 |
Why?
|
Pacemaker, Artificial | 2 | 2017 | 39 | 0.300 |
Why?
|
Coronary Disease | 1 | 2008 | 185 | 0.300 |
Why?
|
Kentucky | 4 | 2020 | 78 | 0.300 |
Why?
|
Receptors, Purinergic P2Y12 | 6 | 2011 | 18 | 0.290 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2020 | 96 | 0.290 |
Why?
|
Tunica Intima | 2 | 2006 | 65 | 0.280 |
Why?
|
Genotype | 4 | 2020 | 636 | 0.280 |
Why?
|
Cell Adhesion | 4 | 2013 | 186 | 0.280 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2015 | 1571 | 0.280 |
Why?
|
Comorbidity | 5 | 2019 | 688 | 0.280 |
Why?
|
Hyperplasia | 4 | 2012 | 120 | 0.270 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 422 | 0.270 |
Why?
|
NF-kappa B | 3 | 2019 | 350 | 0.270 |
Why?
|
Antibodies, Monoclonal | 8 | 2003 | 562 | 0.270 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 425 | 0.270 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 2 | 2013 | 56 | 0.270 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2015 | 64 | 0.270 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2017 | 31 | 0.270 |
Why?
|
Emergency Service, Hospital | 4 | 2021 | 517 | 0.270 |
Why?
|
HIV Infections | 2 | 2019 | 389 | 0.260 |
Why?
|
Sensitivity and Specificity | 4 | 2017 | 970 | 0.260 |
Why?
|
Cell Adhesion Molecules | 4 | 2012 | 97 | 0.260 |
Why?
|
Shock, Septic | 2 | 2017 | 81 | 0.260 |
Why?
|
Recombinant Proteins | 4 | 2012 | 594 | 0.260 |
Why?
|
MicroRNAs | 2 | 2018 | 366 | 0.250 |
Why?
|
Prosthesis Implantation | 2 | 2016 | 63 | 0.250 |
Why?
|
Receptors, Lysosphingolipid | 3 | 2013 | 9 | 0.240 |
Why?
|
Phenotype | 5 | 2014 | 840 | 0.240 |
Why?
|
Follow-Up Studies | 5 | 2019 | 2447 | 0.240 |
Why?
|
Case-Control Studies | 3 | 2019 | 1262 | 0.240 |
Why?
|
Extracellular Matrix | 1 | 2003 | 122 | 0.230 |
Why?
|
Growth Substances | 1 | 2002 | 34 | 0.230 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 7 | 0.230 |
Why?
|
Coronary Restenosis | 1 | 2002 | 39 | 0.230 |
Why?
|
Enzyme Inhibitors | 3 | 2015 | 471 | 0.230 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 3 | 2012 | 110 | 0.230 |
Why?
|
Egtazic Acid | 2 | 2020 | 20 | 0.230 |
Why?
|
Drug Delivery Systems | 2 | 2018 | 154 | 0.220 |
Why?
|
Prognosis | 5 | 2021 | 2104 | 0.220 |
Why?
|
Dietary Fats | 2 | 2022 | 151 | 0.220 |
Why?
|
Apolipoproteins E | 2 | 2014 | 63 | 0.220 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 28 | 0.220 |
Why?
|
Antipyretics | 1 | 2021 | 5 | 0.220 |
Why?
|
Calcium | 3 | 2020 | 470 | 0.220 |
Why?
|
Wound Healing | 3 | 2020 | 220 | 0.220 |
Why?
|
Purinergic P2Y Receptor Antagonists | 4 | 2020 | 34 | 0.210 |
Why?
|
Protein Binding | 7 | 2015 | 784 | 0.210 |
Why?
|
Cell-Derived Microparticles | 2 | 2019 | 23 | 0.210 |
Why?
|
Marital Status | 1 | 2021 | 23 | 0.210 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2021 | 27 | 0.210 |
Why?
|
Cardiac Valve Annuloplasty | 1 | 2020 | 4 | 0.210 |
Why?
|
Cricetinae | 6 | 2015 | 211 | 0.210 |
Why?
|
Angiopoietin-2 | 1 | 2020 | 18 | 0.210 |
Why?
|
Angiopoietin-1 | 1 | 2020 | 21 | 0.210 |
Why?
|
Mice, Inbred BALB C | 3 | 2011 | 380 | 0.210 |
Why?
|
Hypothermia, Induced | 1 | 2021 | 44 | 0.210 |
Why?
|
Liver Cirrhosis | 2 | 2019 | 211 | 0.210 |
Why?
|
Cell Membrane | 4 | 2011 | 283 | 0.210 |
Why?
|
Health Promotion | 2 | 2017 | 301 | 0.210 |
Why?
|
Preoperative Period | 1 | 2020 | 66 | 0.200 |
Why?
|
Cytokines | 3 | 2014 | 700 | 0.200 |
Why?
|
Cold Temperature | 1 | 2020 | 54 | 0.200 |
Why?
|
Reproducibility of Results | 4 | 2018 | 1326 | 0.200 |
Why?
|
Cricetulus | 5 | 2015 | 102 | 0.200 |
Why?
|
Adenosine Diphosphate | 5 | 2014 | 28 | 0.200 |
Why?
|
Transfection | 3 | 2012 | 439 | 0.200 |
Why?
|
Adenosine Monophosphate | 3 | 2020 | 19 | 0.200 |
Why?
|
Granulocytes | 1 | 2020 | 33 | 0.200 |
Why?
|
Portugal | 1 | 2019 | 3 | 0.190 |
Why?
|
Echocardiography | 3 | 2020 | 388 | 0.190 |
Why?
|
Species Specificity | 3 | 2009 | 227 | 0.190 |
Why?
|
Disease-Free Survival | 1 | 2020 | 518 | 0.190 |
Why?
|
Patient Discharge | 2 | 2019 | 325 | 0.190 |
Why?
|
Congresses as Topic | 1 | 2019 | 54 | 0.190 |
Why?
|
Diet, Fat-Restricted | 1 | 2019 | 11 | 0.190 |
Why?
|
CHO Cells | 4 | 2015 | 130 | 0.190 |
Why?
|
Myelopoiesis | 2 | 2020 | 2 | 0.190 |
Why?
|
Hyperlipidemias | 1 | 2019 | 54 | 0.180 |
Why?
|
Serum Amyloid A Protein | 1 | 2019 | 10 | 0.180 |
Why?
|
Molecular Structure | 1 | 2020 | 334 | 0.180 |
Why?
|
rap GTP-Binding Proteins | 2 | 2011 | 4 | 0.180 |
Why?
|
Leukocyte Count | 1 | 2019 | 81 | 0.180 |
Why?
|
Enzyme Activation | 4 | 2012 | 346 | 0.180 |
Why?
|
Ultrasonography, Interventional | 1 | 2020 | 148 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 569 | 0.180 |
Why?
|
Cause of Death | 2 | 2017 | 160 | 0.180 |
Why?
|
Young Adult | 4 | 2018 | 4295 | 0.180 |
Why?
|
Aggression | 1 | 2019 | 65 | 0.180 |
Why?
|
Propensity Score | 1 | 2019 | 135 | 0.180 |
Why?
|
Epigenesis, Genetic | 2 | 2015 | 388 | 0.180 |
Why?
|
Promoter Regions, Genetic | 3 | 2019 | 564 | 0.180 |
Why?
|
Polymerase Chain Reaction | 2 | 2012 | 556 | 0.170 |
Why?
|
Kinetics | 4 | 2007 | 740 | 0.170 |
Why?
|
Mortality | 1 | 2019 | 111 | 0.170 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2018 | 27 | 0.170 |
Why?
|
Thrombopoiesis | 1 | 2018 | 8 | 0.170 |
Why?
|
Hospital Costs | 1 | 2019 | 90 | 0.170 |
Why?
|
Platelet-Rich Plasma | 1 | 2018 | 8 | 0.170 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 263 | 0.170 |
Why?
|
Lymphangiogenesis | 1 | 2018 | 6 | 0.170 |
Why?
|
Lactase | 1 | 2017 | 2 | 0.170 |
Why?
|
Retroperitoneal Space | 1 | 2017 | 29 | 0.170 |
Why?
|
CD40 Ligand | 2 | 2015 | 18 | 0.170 |
Why?
|
Regeneration | 1 | 2018 | 62 | 0.170 |
Why?
|
Extracellular Matrix Proteins | 1 | 2018 | 80 | 0.170 |
Why?
|
Hydrolysis | 2 | 2019 | 78 | 0.160 |
Why?
|
Triglycerides | 1 | 2019 | 205 | 0.160 |
Why?
|
Blood Proteins | 1 | 2018 | 104 | 0.160 |
Why?
|
Adiposity | 1 | 2019 | 144 | 0.160 |
Why?
|
Prosthesis Design | 1 | 2019 | 270 | 0.160 |
Why?
|
Hyperglycemia | 2 | 2010 | 89 | 0.160 |
Why?
|
Thromboembolism | 1 | 2018 | 59 | 0.160 |
Why?
|
Hematoma | 1 | 2017 | 72 | 0.160 |
Why?
|
Patient Compliance | 1 | 2019 | 268 | 0.160 |
Why?
|
Neutrophil Infiltration | 2 | 2014 | 27 | 0.160 |
Why?
|
Protein Kinase C | 4 | 2011 | 79 | 0.160 |
Why?
|
Program Evaluation | 1 | 2019 | 403 | 0.160 |
Why?
|
Heart Injuries | 1 | 2017 | 23 | 0.160 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2009 | 172 | 0.160 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 286 | 0.160 |
Why?
|
Reference Values | 2 | 2008 | 389 | 0.150 |
Why?
|
Academic Medical Centers | 1 | 2017 | 155 | 0.150 |
Why?
|
Lipoproteins | 1 | 2016 | 44 | 0.150 |
Why?
|
Survivors | 1 | 2017 | 128 | 0.150 |
Why?
|
Forecasting | 1 | 2017 | 170 | 0.150 |
Why?
|
Double-Blind Method | 3 | 2015 | 756 | 0.150 |
Why?
|
Exercise Therapy | 1 | 2017 | 122 | 0.150 |
Why?
|
Calgranulin B | 1 | 2016 | 7 | 0.150 |
Why?
|
Receptors, Vitronectin | 2 | 2009 | 3 | 0.150 |
Why?
|
Blood Cell Count | 1 | 2016 | 43 | 0.150 |
Why?
|
Host-Pathogen Interactions | 1 | 2018 | 153 | 0.150 |
Why?
|
Neointima | 2 | 2012 | 14 | 0.150 |
Why?
|
Hypertension | 2 | 2014 | 556 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 191 | 0.140 |
Why?
|
Heart Arrest | 1 | 2017 | 142 | 0.140 |
Why?
|
Membrane Lipids | 2 | 2010 | 16 | 0.140 |
Why?
|
Bone Marrow Transplantation | 2 | 2014 | 164 | 0.140 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2015 | 5 | 0.140 |
Why?
|
Hemophilia B | 1 | 2015 | 4 | 0.140 |
Why?
|
Platelet Factor 4 | 1 | 2015 | 4 | 0.140 |
Why?
|
Vesicular Transport Proteins | 1 | 2015 | 50 | 0.140 |
Why?
|
Cell Aggregation | 1 | 2015 | 8 | 0.140 |
Why?
|
Foam Cells | 1 | 2015 | 19 | 0.140 |
Why?
|
Early Medical Intervention | 1 | 2015 | 10 | 0.140 |
Why?
|
Catheters | 1 | 2015 | 33 | 0.140 |
Why?
|
Purinergic P2 Receptor Antagonists | 3 | 2009 | 7 | 0.140 |
Why?
|
Hemophilia A | 1 | 2015 | 22 | 0.140 |
Why?
|
Fibrinolysis | 2 | 2007 | 10 | 0.140 |
Why?
|
R-SNARE Proteins | 1 | 2014 | 9 | 0.140 |
Why?
|
Protein Structure, Tertiary | 3 | 2011 | 299 | 0.140 |
Why?
|
Healthcare Disparities | 1 | 2018 | 242 | 0.130 |
Why?
|
Up-Regulation | 2 | 2020 | 536 | 0.130 |
Why?
|
Algorithms | 1 | 2019 | 729 | 0.130 |
Why?
|
Microscopy, Electron | 4 | 2002 | 98 | 0.130 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2014 | 4 | 0.130 |
Why?
|
Cardiovascular Agents | 1 | 2015 | 63 | 0.130 |
Why?
|
Homeostasis | 2 | 2022 | 237 | 0.130 |
Why?
|
Phosphatidic Acids | 2 | 2010 | 10 | 0.130 |
Why?
|
Risk | 2 | 2014 | 361 | 0.130 |
Why?
|
Liver Neoplasms | 1 | 2018 | 337 | 0.130 |
Why?
|
Focal Adhesion Kinase 2 | 3 | 2014 | 16 | 0.130 |
Why?
|
Embryo, Mammalian | 2 | 2012 | 72 | 0.130 |
Why?
|
Membrane Glycoproteins | 3 | 2003 | 295 | 0.130 |
Why?
|
Receptor, TIE-2 | 1 | 2014 | 21 | 0.130 |
Why?
|
Ventricular Remodeling | 1 | 2014 | 68 | 0.130 |
Why?
|
Vitamin K | 1 | 2014 | 17 | 0.130 |
Why?
|
Integrases | 1 | 2014 | 47 | 0.130 |
Why?
|
Stem Cells | 1 | 2015 | 194 | 0.130 |
Why?
|
Antithrombins | 1 | 2014 | 22 | 0.130 |
Why?
|
Peptidomimetics | 1 | 2013 | 4 | 0.130 |
Why?
|
Transgenes | 1 | 2014 | 63 | 0.130 |
Why?
|
Lactones | 1 | 2014 | 28 | 0.130 |
Why?
|
Cell Line | 4 | 2013 | 1226 | 0.130 |
Why?
|
Vascular System Injuries | 1 | 2014 | 41 | 0.130 |
Why?
|
Ovarian Neoplasms | 1 | 2018 | 447 | 0.130 |
Why?
|
Amino Acid Sequence | 4 | 2011 | 813 | 0.130 |
Why?
|
Clot Retraction | 2 | 2011 | 2 | 0.120 |
Why?
|
Receptors, Thrombin | 2 | 2014 | 18 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 180 | 0.120 |
Why?
|
Molecular Sequence Data | 4 | 2011 | 1053 | 0.120 |
Why?
|
Dyslipidemias | 1 | 2013 | 40 | 0.120 |
Why?
|
Toll-Like Receptor 4 | 2 | 2014 | 56 | 0.120 |
Why?
|
Lycopersicon esculentum | 1 | 2013 | 36 | 0.120 |
Why?
|
Thionucleosides | 1 | 2012 | 3 | 0.120 |
Why?
|
Exercise | 1 | 2017 | 522 | 0.120 |
Why?
|
Ceramides | 1 | 2013 | 38 | 0.120 |
Why?
|
Heparin | 1 | 2014 | 101 | 0.120 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2013 | 32 | 0.120 |
Why?
|
Ventricular Function, Left | 1 | 2014 | 179 | 0.120 |
Why?
|
Community-Acquired Infections | 1 | 2013 | 41 | 0.120 |
Why?
|
Recovery of Function | 2 | 2020 | 236 | 0.120 |
Why?
|
Cohort Studies | 2 | 2019 | 1532 | 0.120 |
Why?
|
rho-Associated Kinases | 1 | 2012 | 18 | 0.120 |
Why?
|
Digoxin | 1 | 2012 | 33 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 61 | 0.120 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 52 | 0.120 |
Why?
|
Diglycerides | 1 | 1992 | 14 | 0.120 |
Why?
|
Macrophages, Peritoneal | 1 | 2013 | 38 | 0.120 |
Why?
|
RNA, Messenger | 3 | 2012 | 1282 | 0.120 |
Why?
|
Pyridines | 1 | 2014 | 144 | 0.120 |
Why?
|
Fibroblasts | 2 | 2012 | 379 | 0.120 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 217 | 0.120 |
Why?
|
Mitochondrial Proteins | 2 | 2012 | 108 | 0.120 |
Why?
|
Antiplatyhelmintic Agents | 1 | 2012 | 1 | 0.120 |
Why?
|
Carotid Artery, Common | 1 | 2012 | 48 | 0.120 |
Why?
|
Adenosine | 1 | 2012 | 70 | 0.110 |
Why?
|
Adipokines | 1 | 2012 | 15 | 0.110 |
Why?
|
Body Weight | 2 | 2019 | 601 | 0.110 |
Why?
|
Phospholipids | 1 | 1992 | 61 | 0.110 |
Why?
|
Intestine, Small | 1 | 2013 | 142 | 0.110 |
Why?
|
Adolescent | 4 | 2018 | 6866 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 582 | 0.110 |
Why?
|
Subcutaneous Fat | 1 | 2012 | 22 | 0.110 |
Why?
|
Echocardiography, Doppler | 1 | 2012 | 62 | 0.110 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2012 | 96 | 0.110 |
Why?
|
Lyases | 1 | 2011 | 3 | 0.110 |
Why?
|
Macrophage-1 Antigen | 2 | 2014 | 11 | 0.110 |
Why?
|
Drugs, Investigational | 1 | 2012 | 20 | 0.110 |
Why?
|
Drug Discovery | 1 | 2013 | 94 | 0.110 |
Why?
|
Lipopeptides | 1 | 2012 | 64 | 0.110 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2011 | 12 | 0.110 |
Why?
|
Lipoproteins, HDL | 1 | 2011 | 19 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 179 | 0.110 |
Why?
|
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2011 | 1 | 0.110 |
Why?
|
HEK293 Cells | 1 | 2012 | 248 | 0.110 |
Why?
|
Fibrin | 2 | 2001 | 16 | 0.110 |
Why?
|
Ion Channels | 1 | 2012 | 73 | 0.110 |
Why?
|
Guanylate Cyclase | 1 | 2011 | 12 | 0.110 |
Why?
|
Endothelin-1 | 1 | 2011 | 32 | 0.110 |
Why?
|
Organ Size | 2 | 2009 | 262 | 0.110 |
Why?
|
Catalysis | 1 | 2011 | 93 | 0.110 |
Why?
|
Mice, Inbred Strains | 3 | 2019 | 211 | 0.110 |
Why?
|
Electrocardiography | 1 | 2013 | 312 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 1296 | 0.110 |
Why?
|
Odds Ratio | 2 | 2018 | 621 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2014 | 500 | 0.110 |
Why?
|
Random Allocation | 1 | 2012 | 326 | 0.110 |
Why?
|
Thromboplastin | 2 | 2022 | 11 | 0.110 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2011 | 97 | 0.100 |
Why?
|
Erythrocytes | 1 | 2011 | 118 | 0.100 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2010 | 10 | 0.100 |
Why?
|
Nuclear Localization Signals | 1 | 2010 | 7 | 0.100 |
Why?
|
Pluripotent Stem Cells | 1 | 2010 | 10 | 0.100 |
Why?
|
Aorta, Thoracic | 2 | 2008 | 92 | 0.100 |
Why?
|
Lung | 2 | 2011 | 489 | 0.100 |
Why?
|
Drug-Eluting Stents | 1 | 2011 | 114 | 0.100 |
Why?
|
Substrate Specificity | 2 | 2011 | 202 | 0.100 |
Why?
|
Piperazines | 3 | 2020 | 126 | 0.100 |
Why?
|
Asthma | 1 | 2013 | 268 | 0.100 |
Why?
|
Phospholipase C gamma | 1 | 2010 | 5 | 0.100 |
Why?
|
Cardiac Catheterization | 1 | 2013 | 257 | 0.100 |
Why?
|
Thrombospondins | 1 | 2010 | 11 | 0.100 |
Why?
|
Protein Prenylation | 1 | 2010 | 6 | 0.100 |
Why?
|
Massage | 1 | 2009 | 7 | 0.100 |
Why?
|
Polyisoprenyl Phosphates | 1 | 2010 | 19 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2011 | 128 | 0.100 |
Why?
|
Genes, Y-Linked | 1 | 2009 | 1 | 0.100 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 20 | 0.090 |
Why?
|
Tobacco Smoke Pollution | 1 | 2010 | 54 | 0.090 |
Why?
|
Models, Genetic | 2 | 2007 | 204 | 0.090 |
Why?
|
Atrial Natriuretic Factor | 1 | 2009 | 27 | 0.090 |
Why?
|
Lipopolysaccharides | 3 | 2019 | 219 | 0.090 |
Why?
|
Myosin Heavy Chains | 1 | 2009 | 21 | 0.090 |
Why?
|
Disease | 1 | 2009 | 28 | 0.090 |
Why?
|
Immunity | 1 | 2009 | 41 | 0.090 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2009 | 6 | 0.090 |
Why?
|
Heart Valves | 1 | 2009 | 15 | 0.090 |
Why?
|
Pulmonary Edema | 1 | 2009 | 21 | 0.090 |
Why?
|
History, 21st Century | 1 | 2009 | 67 | 0.090 |
Why?
|
Thiazolidinediones | 2 | 2010 | 105 | 0.090 |
Why?
|
Thromboxanes | 1 | 2008 | 2 | 0.090 |
Why?
|
Receptors, Thromboxane | 1 | 2008 | 13 | 0.090 |
Why?
|
Receptors, Purinergic P2Y1 | 1 | 2008 | 8 | 0.090 |
Why?
|
Boronic Acids | 1 | 2010 | 200 | 0.090 |
Why?
|
American Heart Association | 1 | 2009 | 40 | 0.090 |
Why?
|
Endoplasmic Reticulum | 1 | 2010 | 127 | 0.090 |
Why?
|
Calcinosis | 1 | 2009 | 63 | 0.090 |
Why?
|
Multiple Sclerosis | 1 | 2009 | 77 | 0.090 |
Why?
|
History, 20th Century | 1 | 2009 | 127 | 0.090 |
Why?
|
Sesquiterpenes | 1 | 2010 | 95 | 0.090 |
Why?
|
Oligonucleotides | 1 | 2009 | 85 | 0.090 |
Why?
|
Cell Division | 3 | 2006 | 369 | 0.090 |
Why?
|
rho GTP-Binding Proteins | 2 | 2010 | 6 | 0.090 |
Why?
|
Enzymes | 1 | 2008 | 35 | 0.090 |
Why?
|
Nuclear Proteins | 1 | 2010 | 270 | 0.090 |
Why?
|
Models, Animal | 1 | 2009 | 267 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2008 | 138 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 533 | 0.090 |
Why?
|
Delivery of Health Care | 2 | 2021 | 275 | 0.090 |
Why?
|
Pain Management | 1 | 2009 | 155 | 0.080 |
Why?
|
Reperfusion Injury | 1 | 2009 | 119 | 0.080 |
Why?
|
Benzoxazoles | 2 | 2020 | 14 | 0.080 |
Why?
|
Ligands | 3 | 2009 | 254 | 0.080 |
Why?
|
Ferric Compounds | 2 | 2010 | 17 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 521 | 0.080 |
Why?
|
Phosphotyrosine | 1 | 2006 | 9 | 0.080 |
Why?
|
Indicators and Reagents | 1 | 2007 | 58 | 0.080 |
Why?
|
Probability | 1 | 2007 | 186 | 0.080 |
Why?
|
Environment | 1 | 2007 | 106 | 0.080 |
Why?
|
Carbon Radioisotopes | 1 | 2007 | 74 | 0.080 |
Why?
|
Chlorides | 2 | 2010 | 58 | 0.080 |
Why?
|
Lymphocytes | 1 | 2007 | 174 | 0.080 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 14 | 0.080 |
Why?
|
Isotope Labeling | 1 | 2007 | 65 | 0.080 |
Why?
|
E-Selectin | 1 | 2006 | 21 | 0.080 |
Why?
|
Genetic Vectors | 1 | 2007 | 150 | 0.070 |
Why?
|
Lipids | 2 | 2022 | 170 | 0.070 |
Why?
|
Swine | 1 | 2007 | 436 | 0.070 |
Why?
|
Structure-Activity Relationship | 2 | 2000 | 446 | 0.070 |
Why?
|
Mutation | 2 | 2011 | 1428 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 151 | 0.070 |
Why?
|
Heartburn | 1 | 2005 | 4 | 0.070 |
Why?
|
Dyspepsia | 1 | 2005 | 11 | 0.070 |
Why?
|
Analysis of Variance | 1 | 2007 | 674 | 0.070 |
Why?
|
Anti-Ulcer Agents | 1 | 2005 | 23 | 0.070 |
Why?
|
Histamine H2 Antagonists | 1 | 2005 | 27 | 0.070 |
Why?
|
Causality | 2 | 2016 | 50 | 0.070 |
Why?
|
Precipitin Tests | 2 | 2003 | 45 | 0.070 |
Why?
|
Lipoproteins, LDL | 2 | 2019 | 214 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2019 | 162 | 0.070 |
Why?
|
Gene Deletion | 2 | 2020 | 292 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 713 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2019 | 153 | 0.070 |
Why?
|
Fibrinolysin | 2 | 2001 | 3 | 0.070 |
Why?
|
Tandem Mass Spectrometry | 2 | 2018 | 243 | 0.070 |
Why?
|
Carrier Proteins | 3 | 2015 | 377 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 712 | 0.070 |
Why?
|
Proton Pump Inhibitors | 1 | 2005 | 91 | 0.070 |
Why?
|
Immunohistochemistry | 3 | 2002 | 1140 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2005 | 188 | 0.060 |
Why?
|
Focal Adhesions | 1 | 2003 | 14 | 0.060 |
Why?
|
Receptor Aggregation | 1 | 2003 | 1 | 0.060 |
Why?
|
Biotinylation | 1 | 2003 | 39 | 0.060 |
Why?
|
Edetic Acid | 1 | 2003 | 18 | 0.060 |
Why?
|
Quality of Life | 3 | 2021 | 820 | 0.060 |
Why?
|
Models, Chemical | 1 | 2003 | 71 | 0.060 |
Why?
|
Glycosylation | 1 | 2003 | 111 | 0.060 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 1983 | 8 | 0.060 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2003 | 195 | 0.060 |
Why?
|
Carotid Arteries | 3 | 2009 | 92 | 0.060 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2013 | 44 | 0.060 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2002 | 25 | 0.060 |
Why?
|
Liver Diseases | 1 | 1983 | 85 | 0.060 |
Why?
|
Apoptosis | 2 | 2020 | 1357 | 0.060 |
Why?
|
Biotin | 1 | 2003 | 162 | 0.060 |
Why?
|
Carotid Artery Thrombosis | 1 | 2001 | 6 | 0.060 |
Why?
|
Factor XIIIa | 1 | 2001 | 11 | 0.050 |
Why?
|
Microscopy, Fluorescence | 2 | 2013 | 204 | 0.050 |
Why?
|
Phosphate-Binding Proteins | 1 | 2021 | 6 | 0.050 |
Why?
|
Prevalence | 2 | 2016 | 994 | 0.050 |
Why?
|
Coma | 1 | 2021 | 17 | 0.050 |
Why?
|
Matrix Metalloproteinases | 1 | 2001 | 56 | 0.050 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2001 | 40 | 0.050 |
Why?
|
Cytoskeleton | 2 | 2009 | 53 | 0.050 |
Why?
|
Chelating Agents | 2 | 2011 | 34 | 0.050 |
Why?
|
Pancreatic Elastase | 1 | 2020 | 10 | 0.050 |
Why?
|
Kidney | 1 | 2007 | 834 | 0.050 |
Why?
|
Microfilament Proteins | 2 | 2012 | 52 | 0.050 |
Why?
|
Glycoproteins | 2 | 2013 | 139 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2013 | 295 | 0.050 |
Why?
|
Rats | 4 | 2011 | 3599 | 0.050 |
Why?
|
Evidence-Based Practice | 1 | 2021 | 115 | 0.050 |
Why?
|
Interferon-beta | 1 | 2020 | 30 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2020 | 53 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 146 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 3 | 2010 | 235 | 0.050 |
Why?
|
Gadolinium | 1 | 2020 | 62 | 0.050 |
Why?
|
Phosphoproteins | 2 | 2012 | 122 | 0.050 |
Why?
|
Cell Count | 1 | 2020 | 195 | 0.050 |
Why?
|
Unnecessary Procedures | 1 | 2020 | 29 | 0.050 |
Why?
|
Organizational Innovation | 1 | 2020 | 43 | 0.050 |
Why?
|
Hybridomas | 1 | 1999 | 19 | 0.050 |
Why?
|
Transcription Factor RelB | 1 | 2019 | 4 | 0.050 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2019 | 19 | 0.050 |
Why?
|
Histones | 1 | 2022 | 333 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2001 | 169 | 0.050 |
Why?
|
I-kappa B Proteins | 1 | 2019 | 29 | 0.050 |
Why?
|
Transcription Factor RelA | 1 | 2019 | 38 | 0.050 |
Why?
|
Hypolipidemic Agents | 1 | 2019 | 38 | 0.050 |
Why?
|
Antigens | 1 | 1999 | 57 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 1118 | 0.050 |
Why?
|
Focus Groups | 1 | 2020 | 209 | 0.050 |
Why?
|
Cyclic AMP | 2 | 2012 | 117 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2019 | 115 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2020 | 331 | 0.050 |
Why?
|
Contrast Media | 1 | 2020 | 241 | 0.040 |
Why?
|
Skilled Nursing Facilities | 1 | 2018 | 9 | 0.040 |
Why?
|
Siblings | 1 | 2019 | 42 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2012 | 130 | 0.040 |
Why?
|
Sex Distribution | 1 | 2019 | 163 | 0.040 |
Why?
|
Brain | 2 | 2001 | 1458 | 0.040 |
Why?
|
Caspases | 1 | 2019 | 153 | 0.040 |
Why?
|
Bacterial Infections | 1 | 2019 | 105 | 0.040 |
Why?
|
Delphi Technique | 1 | 2017 | 35 | 0.040 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2018 | 69 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2019 | 465 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 332 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 528 | 0.040 |
Why?
|
Proteins | 1 | 2000 | 406 | 0.040 |
Why?
|
Equipment Failure | 1 | 2017 | 79 | 0.040 |
Why?
|
Receptors, Complement | 1 | 1996 | 5 | 0.040 |
Why?
|
Complement C1q | 1 | 1996 | 12 | 0.040 |
Why?
|
Pandemics | 1 | 2022 | 467 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2018 | 243 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 1503 | 0.040 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1993 | 129 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2018 | 698 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2018 | 219 | 0.040 |
Why?
|
Transcription Factors | 1 | 2019 | 645 | 0.030 |
Why?
|
Health Care Costs | 1 | 2016 | 180 | 0.030 |
Why?
|
Genetic Loci | 1 | 2015 | 63 | 0.030 |
Why?
|
Medication Therapy Management | 1 | 2015 | 25 | 0.030 |
Why?
|
Protein Transport | 1 | 2015 | 205 | 0.030 |
Why?
|
Subcellular Fractions | 1 | 2014 | 44 | 0.030 |
Why?
|
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 2014 | 1 | 0.030 |
Why?
|
SNARE Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
Rolipram | 1 | 2014 | 5 | 0.030 |
Why?
|
Receptors, Interleukin-1 | 1 | 2014 | 19 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 1577 | 0.030 |
Why?
|
Imidazoles | 1 | 2015 | 153 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2014 | 55 | 0.030 |
Why?
|
Cell Separation | 1 | 2014 | 115 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2014 | 39 | 0.030 |
Why?
|
Consensus | 1 | 2015 | 147 | 0.030 |
Why?
|
Binding Sites | 2 | 2011 | 471 | 0.030 |
Why?
|
Western World | 1 | 2013 | 3 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 68 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2013 | 9 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 435 | 0.030 |
Why?
|
North America | 1 | 2014 | 71 | 0.030 |
Why?
|
Plants, Genetically Modified | 1 | 2013 | 24 | 0.030 |
Why?
|
Europe | 1 | 2014 | 106 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 215 | 0.030 |
Why?
|
Cell Fractionation | 1 | 1993 | 19 | 0.030 |
Why?
|
Centrifugation, Density Gradient | 1 | 1993 | 25 | 0.030 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2013 | 29 | 0.030 |
Why?
|
Cations, Divalent | 1 | 1993 | 9 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2014 | 100 | 0.030 |
Why?
|
Half-Life | 1 | 2013 | 101 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 896 | 0.030 |
Why?
|
beta-Defensins | 1 | 2013 | 6 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2013 | 189 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2013 | 76 | 0.030 |
Why?
|
Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 1 | 0.030 |
Why?
|
Cyclooxygenase 1 | 1 | 2013 | 7 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2012 | 4 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 33 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 32 | 0.030 |
Why?
|
Disease Management | 1 | 2015 | 199 | 0.030 |
Why?
|
Epoprostenol | 1 | 2012 | 29 | 0.030 |
Why?
|
Epitopes | 1 | 1993 | 89 | 0.030 |
Why?
|
Dinoprostone | 1 | 2013 | 50 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2014 | 324 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2013 | 31 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2013 | 83 | 0.030 |
Why?
|
Glycerophosphates | 1 | 1992 | 3 | 0.030 |
Why?
|
Chromatography, DEAE-Cellulose | 1 | 1992 | 8 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 1992 | 33 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1992 | 52 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2013 | 93 | 0.030 |
Why?
|
African Americans | 1 | 2018 | 715 | 0.030 |
Why?
|
Oligopeptides | 1 | 1993 | 98 | 0.030 |
Why?
|
Chromatography, Affinity | 1 | 1992 | 48 | 0.030 |
Why?
|
Protein Conformation | 1 | 1993 | 234 | 0.030 |
Why?
|
Allergens | 1 | 2013 | 133 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2012 | 22 | 0.030 |
Why?
|
Integrin beta4 | 1 | 2011 | 1 | 0.030 |
Why?
|
Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2011 | 7 | 0.030 |
Why?
|
Hepatocytes | 1 | 2013 | 210 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2012 | 85 | 0.030 |
Why?
|
Thioglycolates | 1 | 2011 | 8 | 0.030 |
Why?
|
Bone Marrow | 1 | 2014 | 413 | 0.030 |
Why?
|
Peritoneum | 1 | 2011 | 12 | 0.030 |
Why?
|
Oncogene Protein v-akt | 1 | 2011 | 13 | 0.030 |
Why?
|
Cyclic GMP | 1 | 2011 | 23 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2011 | 89 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2011 | 75 | 0.030 |
Why?
|
Ligation | 1 | 2011 | 67 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 569 | 0.030 |
Why?
|
Thiophenes | 1 | 2011 | 46 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 458 | 0.030 |
Why?
|
Organ Specificity | 1 | 2011 | 128 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 543 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 535 | 0.030 |
Why?
|
Primary Prevention | 1 | 2011 | 49 | 0.030 |
Why?
|
Stage-Specific Embryonic Antigens | 1 | 2010 | 1 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2010 | 3 | 0.030 |
Why?
|
Antibody Specificity | 2 | 2001 | 46 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2011 | 65 | 0.030 |
Why?
|
alpha Karyopherins | 1 | 2010 | 2 | 0.030 |
Why?
|
Phospholipase D | 1 | 2010 | 6 | 0.030 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2010 | 48 | 0.030 |
Why?
|
Serine | 1 | 2010 | 45 | 0.030 |
Why?
|
Liposomes | 1 | 2010 | 48 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2011 | 176 | 0.030 |
Why?
|
Equipment Design | 1 | 2011 | 337 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2010 | 158 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2011 | 235 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 128 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2010 | 157 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 84 | 0.020 |
Why?
|
Eye | 1 | 2010 | 37 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 208 | 0.020 |
Why?
|
Blotting, Western | 1 | 2011 | 721 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 199 | 0.020 |
Why?
|
Cattle | 1 | 2010 | 225 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2009 | 14 | 0.020 |
Why?
|
Survival | 1 | 2009 | 17 | 0.020 |
Why?
|
Warm Ischemia | 1 | 2009 | 6 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2010 | 163 | 0.020 |
Why?
|
Glucosamine | 1 | 2009 | 13 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2010 | 266 | 0.020 |
Why?
|
Paracrine Communication | 1 | 2009 | 18 | 0.020 |
Why?
|
Calcineurin | 1 | 2010 | 72 | 0.020 |
Why?
|
HeLa Cells | 1 | 2010 | 301 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2009 | 112 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2011 | 298 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 229 | 0.020 |
Why?
|
Receptors, Purinergic P2 | 1 | 2009 | 40 | 0.020 |
Why?
|
Fatigue | 1 | 2009 | 134 | 0.020 |
Why?
|
Indoles | 1 | 2011 | 291 | 0.020 |
Why?
|
Actins | 1 | 2009 | 140 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2009 | 183 | 0.020 |
Why?
|
Pain Measurement | 1 | 2009 | 262 | 0.020 |
Why?
|
Alleles | 1 | 2009 | 280 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2009 | 214 | 0.020 |
Why?
|
Partial Thromboplastin Time | 1 | 2007 | 12 | 0.020 |
Why?
|
Prothrombin Time | 1 | 2007 | 20 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2007 | 121 | 0.020 |
Why?
|
Patient Selection | 1 | 2009 | 300 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2010 | 757 | 0.020 |
Why?
|
Liver | 1 | 2013 | 1266 | 0.020 |
Why?
|
Rheology | 1 | 2006 | 16 | 0.020 |
Why?
|
Pain | 1 | 2009 | 389 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2006 | 106 | 0.020 |
Why?
|
Ranitidine | 1 | 2005 | 8 | 0.020 |
Why?
|
Omeprazole | 1 | 2005 | 20 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 1067 | 0.020 |
Why?
|
Purinergic Antagonists | 1 | 2005 | 2 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2006 | 185 | 0.020 |
Why?
|
Ultrasonography | 1 | 2006 | 495 | 0.020 |
Why?
|
Collagen | 1 | 2005 | 234 | 0.020 |
Why?
|
Prealbumin | 1 | 1983 | 25 | 0.020 |
Why?
|
Recurrence | 1 | 2005 | 694 | 0.020 |
Why?
|
Liver Function Tests | 1 | 1983 | 47 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 1983 | 19 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2006 | 316 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 2002 | 16 | 0.010 |
Why?
|
Iliac Artery | 1 | 2002 | 45 | 0.010 |
Why?
|
Aorta, Abdominal | 1 | 2002 | 50 | 0.010 |
Why?
|
Aorta | 1 | 2003 | 184 | 0.010 |
Why?
|
Collagen Type IV | 1 | 2001 | 13 | 0.010 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2001 | 13 | 0.010 |
Why?
|
Nonlinear Dynamics | 1 | 2001 | 25 | 0.010 |
Why?
|
Laminin | 1 | 2001 | 34 | 0.010 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2001 | 70 | 0.010 |
Why?
|
Blood-Brain Barrier | 1 | 2001 | 65 | 0.010 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2001 | 102 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2001 | 259 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2001 | 155 | 0.010 |
Why?
|
Cell Fusion | 1 | 1999 | 20 | 0.010 |
Why?
|
Molecular Weight | 1 | 1999 | 106 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2003 | 1810 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 318 | 0.010 |
Why?
|
Umbilical Veins | 1 | 1996 | 25 | 0.010 |
Why?
|
Phorbol Esters | 1 | 1991 | 6 | 0.010 |
Why?
|
Prostaglandin Endoperoxides, Synthetic | 1 | 1991 | 8 | 0.010 |
Why?
|
Autoradiography | 1 | 1991 | 41 | 0.010 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1991 | 42 | 0.010 |
Why?
|
Protein Kinases | 1 | 1991 | 95 | 0.010 |
Why?
|
Amino Acids | 1 | 1991 | 368 | 0.010 |
Why?
|